166 related articles for article (PubMed ID: 35567637)
21. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
22. [Value of surgery for stage IIIa non-small cell lung cancer].
Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
[TBL] [Abstract][Full Text] [Related]
23. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
24. Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers.
Chapman CG; Ayoub F; Swei E; Llano EM; Li B; Siddiqui UD; Waxman I
Pancreatology; 2020 Dec; 20(8):1747-1754. PubMed ID: 33082106
[TBL] [Abstract][Full Text] [Related]
25. Outcome prediction in resectable lung adenocarcinoma patients: value of CT radiomics.
Choe J; Lee SM; Do KH; Kim S; Choi S; Lee JG; Seo JB
Eur Radiol; 2020 Sep; 30(9):4952-4963. PubMed ID: 32356158
[TBL] [Abstract][Full Text] [Related]
26. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
27. Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials.
Shukla S; Babcock Z; Pizzi L; Brunetti L
Curr Med Res Opin; 2021 May; 37(5):811-817. PubMed ID: 33685311
[TBL] [Abstract][Full Text] [Related]
28. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
[TBL] [Abstract][Full Text] [Related]
29. [Urine metabolomics analysis based on ultra performance liquid chromatography-high resolution mass spectrometry combined with osmolality calibration sample concentration variability].
He Z; Lin H; Gui J; Zhu W; He J; Wang H; Feng L
Se Pu; 2021 Apr; 39(4):391-398. PubMed ID: 34227759
[TBL] [Abstract][Full Text] [Related]
30. High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Hashemi Sadraei N; Feng Y; Du L; Fu P; Haque S; Dowlati A; Gollamudi J; Pennell NA; Mekhail T; Avril S; Farver C; Gerson SL; Sharma N
Lung Cancer; 2018 Dec; 126():48-54. PubMed ID: 30527192
[TBL] [Abstract][Full Text] [Related]
31. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Horne ZD; Clump DA; Vargo JA; Shah S; Beriwal S; Burton SA; Quinn AE; Schuchert MJ; Landreneau RJ; Christie NA; Luketich JD; Heron DE
Radiat Oncol; 2014 Jan; 9():41. PubMed ID: 24479954
[TBL] [Abstract][Full Text] [Related]
33. Study of the metabolomic relationship between lung cancer and chronic obstructive pulmonary disease based on direct infusion mass spectrometry.
Callejón-Leblic B; Pereira-Vega A; Vázquez-Gandullo E; Sánchez-Ramos JL; Gómez-Ariza JL; García-Barrera T
Biochimie; 2019 Feb; 157():111-122. PubMed ID: 30439409
[TBL] [Abstract][Full Text] [Related]
34. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer.
Xie H; Wei L; Gao S; Liu M; Liang Y; Yuan G; Wang Q; Xu Y; Tang S; Gan J
Front Nutr; 2023; 10():1076589. PubMed ID: 36819674
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Prognostic Values of Various PET Metrics in Preoperative
Steiger S; Arvanitakis M; Sick B; Weder W; Hillinger S; Burger IA
J Nucl Med; 2017 Dec; 58(12):1925-1930. PubMed ID: 28490471
[TBL] [Abstract][Full Text] [Related]
38. [Prognostic study of visceral pleural invasion by pulmonary adenocarcinoma with tumor size ≤3 cm].
Chen TY; Ma HW; Jin RR; Xu C; Hua HJ; Song GX; Zhang WM; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):553-558. PubMed ID: 28810296
[No Abstract] [Full Text] [Related]
39. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.
Miura Y; Imai H; Sakurai R; Kaira K; Sunaga N; Minato K; Saito R; Hisada T
Med Oncol; 2018 Mar; 35(4):45. PubMed ID: 29508094
[TBL] [Abstract][Full Text] [Related]
40. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
